Sutro Biopharma, Inc. (NASDAQ:STRO – Get Free Report) was the recipient of a significant growth in short interest during the month of June. As of June 15th, there was short interest totalling 2,290,000 shares, a growth of 20.5% from the May 31st total of 1,900,000 shares. Based on an average daily volume of 978,300 shares, the days-to-cover ratio is presently 2.3 days.
Sutro Biopharma Trading Up 1.0 %
Shares of NASDAQ STRO traded up $0.03 during trading hours on Monday, reaching $2.96. The stock had a trading volume of 373,154 shares, compared to its average volume of 936,947. The firm has a market cap of $242.11 million, a price-to-earnings ratio of -1.56 and a beta of 1.24. The business’s fifty day moving average price is $3.79 and its two-hundred day moving average price is $4.18. Sutro Biopharma has a 52-week low of $2.01 and a 52-week high of $6.13.
Sutro Biopharma (NASDAQ:STRO – Get Free Report) last announced its quarterly earnings results on Monday, May 13th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.03). The firm had revenue of $13.01 million during the quarter, compared to analysts’ expectations of $11.57 million. Sutro Biopharma had a negative net margin of 74.61% and a negative return on equity of 94.18%. Equities research analysts anticipate that Sutro Biopharma will post -3.19 earnings per share for the current fiscal year.
Institutional Trading of Sutro Biopharma
Wall Street Analysts Forecast Growth
Several brokerages have weighed in on STRO. HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of Sutro Biopharma in a research note on Tuesday, May 14th. JMP Securities reissued a “market outperform” rating and set a $17.00 price objective on shares of Sutro Biopharma in a research note on Wednesday, April 3rd. Wedbush reissued an “outperform” rating and set a $8.00 price objective on shares of Sutro Biopharma in a research note on Tuesday, May 14th. Oppenheimer reissued an “outperform” rating and set a $10.00 price objective on shares of Sutro Biopharma in a research note on Wednesday, May 15th. Finally, Piper Sandler reissued an “overweight” rating and set a $11.00 price objective (down from $12.00) on shares of Sutro Biopharma in a research note on Wednesday, April 3rd. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $12.50.
Read Our Latest Analysis on STRO
Sutro Biopharma Company Profile
Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.
Featured Articles
- Five stocks we like better than Sutro Biopharma
- How to Calculate Retirement Income: MarketBeat’s Calculator
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- What Investors Need to Know to Beat the Market
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.